Literature DB >> 18184075

Morbidity before and after HAART initiation in Sub-Saharan African HIV-infected adults: a recurrent event analysis.

Catherine Seyler1, Eugène Messou, Delphine Gabillard, André Inwoley, Ahmadou Alioum, Xavier Anglaret.   

Abstract

The incidence and determinants of severe morbidity recurrence in sub-Saharan African HIV-infected adults on antiretroviral therapy (ART) have never been reported. In a prospective cohort study of HIV-infected adults in Abidjan the association of severe morbidity occurrence and recurrence with follow-up CD4 counts and ART on/off status was analyzed by means of multivariate failure analysis for recurrent events (Prentice, Williams, and Peterson model). A total of 608 patients (median CD4 290/mm3 ) was followed off ART for 1824 person-years (PY). Of these 187 started HAART (median CD4 174/mm3 ) and were followed for 328 PY. The incidence of first, second, and third severe morbidity events was 40.6/100 PY, 68.4/100 PY, and 93.9/100 PY during the off-ART period, and 28.4/100 PY, 39.4/100 PY, and 37.6/100 PY during the on-ART period, respectively. The rates of recurrences were higher than the rates of first episodes for almost all diseases, even after stratifying by CD4 count and by ART on/off status. In multivariate analysis, the time-updated CD4 count was independently associated with increasing rates of morbidity first events and recurrences, after adjustment on other covariates (p > 10(4) ). By contrast, there was no association between the ART on/off status and the morbidity rates after adjustment for CD4 count (p = 0.37). Introducing ART led to a clear reduction in morbidity, mainly related to the ART-induced increase in CD4 count. In HIV-infected patients on ART, the incidence of severe morbidity varied with the past history of morbidity. The past history of morbidity should be taken into account when comparing HIV morbidity rates before and after ART initiation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18184075     DOI: 10.1089/aid.2006.0308

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  19 in total

1.  Mortality, AIDS-morbidity, and loss to follow-up by current CD4 cell count among HIV-1-infected adults receiving antiretroviral therapy in Africa and Asia: data from the ANRS 12222 collaboration.

Authors:  Delphine Gabillard; Charlotte Lewden; Ibra Ndoye; Raoul Moh; Olivier Segeral; Besigin Tonwe-Gold; Jean-François Etard; Men Pagnaroat; Isabelle Fournier-Nicolle; Serge Eholié; Issouf Konate; Albert Minga; Eitel Mpoudi-Ngole; Sinata Koulla-Shiro; Djimon Marcel Zannou; Xavier Anglaret; Christian Laurent
Journal:  J Acquir Immune Defic Syndr       Date:  2013-04-15       Impact factor: 3.731

2.  Could early antiretroviral therapy entail more risks than benefits in sub-Saharan African HIV-infected adults? A model-based analysis.

Authors:  Xavier Anglaret; Callie A Scott; Rochelle P Walensky; Eric Ouattara; Elena Losina; Raoul Moh; Jessica E Becker; Lauren Uhler; Christine Danel; Eugene Messou; Serge Eholié; Kenneth A Freedberg
Journal:  Antivir Ther       Date:  2012-07-18

3.  Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness.

Authors:  April D Kimmel; Milton C Weinstein; Xavier Anglaret; Sue J Goldie; Elena Losina; Yazdan Yazdanpanah; Eugène Messou; Kara L Cotich; Rochelle P Walensky; Kenneth A Freedberg
Journal:  J Acquir Immune Defic Syndr       Date:  2010-07       Impact factor: 3.731

4.  Patient- and population-level health consequences of discontinuing antiretroviral therapy in settings with inadequate HIV treatment availability.

Authors:  April D Kimmel; Stephen C Resch; Xavier Anglaret; Norman Daniels; Sue J Goldie; Christine Danel; Angela Y Wong; Kenneth A Freedberg; Milton C Weinstein
Journal:  Cost Eff Resour Alloc       Date:  2012-09-19

5.  Incidence and determinants of new AIDS-defining illnesses after HAART initiation in a Senegalese cohort.

Authors:  Pierre De Beaudrap; Jean-François Etard; Assane Diouf; Ibrahima Ndiaye; Guèye Fatou N Ndèye; Papa S Sow; Kane Coumba T Ndèye; René Ecochard; Eric Delaporte
Journal:  BMC Infect Dis       Date:  2010-06-19       Impact factor: 3.090

6.  High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lomé, Togo.

Authors:  Anoumou Y Dagnra; Nicole Vidal; Akovi Mensah; Akouda Patassi; Komi Aho; Mounerou Salou; Marjorie Monleau; Mireille Prince-David; Assétina Singo; Palokinam Pitche; Eric Delaporte; Martine Peeters
Journal:  J Int AIDS Soc       Date:  2011-06-10       Impact factor: 5.396

7.  Antiretroviral treatment cohort analysis using time-updated CD4 counts: assessment of bias with different analytic methods.

Authors:  Katharina Kranzer; James J Lewis; Richard G White; Judith R Glynn; Stephen D Lawn; Keren Middelkoop; Linda-Gail Bekker; Robin Wood
Journal:  PLoS One       Date:  2011-11-17       Impact factor: 3.240

8.  The cost-effectiveness of tuberculosis preventive therapy for HIV-infected individuals in southern India: a trial-based analysis.

Authors:  Mai T Pho; Soumya Swaminathan; Nagalingeswaran Kumarasamy; Elena Losina; C Ponnuraja; Lauren M Uhler; Callie A Scott; Kenneth H Mayer; Kenneth A Freedberg; Rochelle P Walensky
Journal:  PLoS One       Date:  2012-04-30       Impact factor: 3.240

9.  Early severe morbidity and resource utilization in South African adults on antiretroviral therapy.

Authors:  Teresa K Smith de Cherif; Jan H Schoeman; Susan Cleary; Graeme A Meintjes; Kevin Rebe; Gary Maartens
Journal:  BMC Infect Dis       Date:  2009-12-15       Impact factor: 3.090

10.  Lipid Profile of Anti-Retroviral Treatment-Naïve HIV-Infected Patients in Jos, Nigeria.

Authors:  Ca Daniyam; Mo Iroezindu
Journal:  Ann Med Health Sci Res       Date:  2013-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.